Scientific Programme

Sunday 30 April 2017
14:15 - 16:45
Meer info
Parents of the Dutch CMV Foundation Speaker1 Speaker2 Speaker3
16:00 - 17:30
Meer info
Opening Session
16:00 - 16:15
Welcome Ann Vossen, Clinical Virologist Leiden University Medical Center , Leiden, Netherlands
16:15 - 16:25
Introduction of Louis Picker René van Lier , Director of Sanquin Research and member of Sanquin's Executive Board Sanquin Blood Supply Foundation and AMC, Amsterdam, Netherlands
16:25 - 17:25
Opening Keynote Lecture - Programming T Cell Immunity: (Advanced) Lessons from Cytomegalovirus Louis J. Picker Oregon Health & Science University , United States of America
Speaker1 Speaker2 Speaker3
Monday 1 May 2017
08:30 - 10:25
Meer info
Session A.01: Epidemiology & Burden of Disease

Chairs: Ben van der Zeijst & Paul Griffiths

08:30 - 09:10
Keynote Lecture: Is CMV really an important pathogen? Paul Griffiths, Professor of Virology University College London Medical School, London , United Kingdom
09:10 - 09:40
Community Engagement to Improve Prevention and Treatment of Congenital Cytomegalovirus Infection Laura Gibson University of Massachusetts Medical School, WORCESTER, MA, United States of Amercia
09:40 - 09:55
Cost of illness of congenital CMV infection Marjolein Korndewal Leiden University Medical Center, Leiden, Netherlands
09:55 - 10:10
First outcomes of an international project on a universal neonatal screening for congenital CMV infections Katrin Neumann Ruhr University Bochum, Bochum, Germany
10:10 - 10:25
Characteristics and Hearing Outcomes of Symptomatic Congenital CMV Infection: Findings from the CHIMES Study Shannon Ross The University of Alabama at Birmingham, Birmingham, United States of America
Speaker1 Speaker2 Speaker3
10:55 - 12:55
Meer info
Session B.01: Virus and Host

Chairs: Klaus Frueh & Martin Messerle

10:55 - 11:25
Invited Lecture: How, when, and why CMV acts like an RNA virus. Timothy Kowalik, Associate Professor University of Massachusetts Medical School, Worchester, United States of America
11:25 - 11:55
Invited Lecture: Fetal immunity or tolerance to CMV infection Arnaud Marchant, Director, Institute for Medical Immunology Université Libre de Bruxelles, Charleroi, Belgium
11:55 - 12:10
Role of cytoplasmic receptors NOD1 and NOD2 in CMV control Ravit Boger Johns Hopkins University School of Medicine, Baltimore, United States of America
12:10 - 12:25
The Human Cytomegalovirus tegument protein pp65 (pUL83) dampens interferon-type I production by inactivating the DNA sensor cGAS Valentina Dell'Oste Università degli Studi di Torino, Torino, Italy
12:25 - 12:40
Human cytomegalovirus genome replication is inhibited in mature Langerhans-type dendritic cells. Laura Hertel Children's Hospital Oakland Research Institute, Oakland, United States of America
12:40 - 12:55
CMV abrogates CD8 T-cell control by inhibiting apoptosis, not by inhibiting antigen presentation M. Zeeshan Chaudhry Helmholtz Center for Infection Studies, Braunschweig, Germany
Speaker1 Speaker2 Speaker3
14:15 - 15:45
Meer info
Session B.02: Virus and Host

Chairs: Stipan Jonjic  & Juliet Spencer

14:15 - 14:45
Invited Lecture: Cytomegalovirus-encoded Fcγ-Receptors: how to avert antibody effector functions? Hartmut Hengel, Head Institute of Virology University Medical Center - Albert-Ludwigs-University Freiburg, Freiburg, Germany
14:45 - 15:00
The contribution of CMV infection to immune senescence is set by the initial viral inoculum Anke Redeker Leiden University Medical Center, Leiden, Netherlands
15:00 - 15:15
Simultaneous analysis by mass cytometry (CyTOF) of impact of human cytomegalovirus-encoded homologs of hIL-10 on multiple cellular signalling pathways Selmir Avdic Discipline of Infectious Diseases and Immunology, the University of Sydney, Camperdown, Australia
15:15 - 15:30
Cytomegalovirus-encoded Death Suppressors Cooperate to Prevent Proinflammatory Consequences of Combined Apoptosis and Necroptosis. Ed Mocarski, Robert W. Woodruff Professor Emory University School of Medicine, Atlanta, United States of America
15:30 - 15:45
Mast cells as rapid innate sensors of cytomegalovirus by TLR3/TRIF signaling-dependent and -independent mechanisms Niels Lemmermann University Medical Center Mainz, Mainz, Germany
Speaker1 Speaker2 Speaker3
16:00 - 17:00
Meer info
Poster Presentation Track A

Poster presenters will be standing by their poster to answer questions from Conference delegates. An overview of the posters per track can be found HERE.

Speaker1 Speaker2 Speaker3
17:00 - 18:15
Meer info
Session C.01: Clinical Practice, Problems & Solutions

Chairs: Ester Remmerswaal & Andreas Moosmann

17:00 - 17:30
Invited Lecture: CMV, ageing T cells and immune defense in the immune comprised host. Michiel Betjes, Nephrologist Erasmus Medical Center, Rotterdam, Netherlands
17:30 - 17:45
Challenges and opportunities in sequencing complete human cytomegalovirus genomes directly from clinical material Nicolás Suárez, Research Associate MRC-University of Glasgow Centre for Virus Research, GLASGOW, United Kingdom
17:45 - 18:00
Clinical validation of T-Track® CMV to assess the functionality of CMV-specific cell-mediated immunity in kidney transplant recipients Anne Rascle Lophius Biosciences, Regensburg, Germany
18:00 - 18:15
CYTOMEGALOVIRUS-SPECIFIC CD8+ T-CELL IMMUNITY IN NEONATES WITH CONGENITAL INFECTION: CORRELATION WITH CLINICAL AND LABORATORY FINDINGS Concetta Marsico University of Bologna, Bologna, Italy
Speaker1 Speaker2 Speaker3
Tuesday 2 May 2017
08:30 - 10:25
Meer info
Session B.03: Virus and Host

Chairs: Ian Humphreys & René van Lier

08:30 - 09:10
Keynote Lecture: Using the Nonhuman Primate Model to Inform Clinical Prevention and Therapeutic Interventions Against Human CMV Peter A. Barry, Professor; Director UC Davis, Davis, California, United States of America
09:10 - 09:25
Cytomegalovirus reactivation in bone marrow transplantation: is controlling graft-versus-host disease important? Paulo Martins QIMR Berghofer, Brisbane, Australia
09:25 - 09:40
Infection of the salivary gland by MCMV is dispensable for formation and persistence of salivary gland CD8+ TRM Sofia Caldeira-Dantas Thomas Jefferson University, Philadelphia, United States of America
09:40 - 09:55
Changes in the total cell proteome during human cytomegalovirus latency - insights into effects on latently infected monocytes Emma Poole University of Cambridge, Cambridge, United Kingdom
09:55 - 10:10
HCMV reinfection in congenitally infected infants: an evolutionary perspective Cornelia Pokalyuk Goethe University - Institute for Mathematics, Frankfurt, Germany
10:10 - 10:25
Control of immune ligands by members of the cytomegalovirus US12 gene family suppresses natural killer cell activation Ceri Fielding Cardiff University, Cardiff, United Kingdom
Speaker1 Speaker2 Speaker3
10:55 - 13:00
Meer info
Session C.02: Clinical Practice, Problems & Solutions

Chairs:  Jantien Bolt-Wieringa & Ann Vossen

10:55 - 11:25
Invited Lecture: Quality control in molecular CMV diagnostics Rob Schuurman, Medical Molecular Microbiologist UMCU, Utrecht, Netherlands
11:25 - 11:30
Introduction to Clinical cases Ann Vossen, Clinical Virologist Leiden University Medical Center , Leiden, Netherlands

During this interactive session three clinical cases will be presented. By using an audience response system the knowledge, practice and experience of the audience in the fields of epidemiology, diagnostics, clinical presentation, antiviral therapy etc. will be tested. The best answer will be supported by evidence, if available, and some of the given answers will be evaluated according to country or profession. For the winner there will be a nice award.

11:30 - 12:00
Clinical case 1: Cytomegalovirus infection in pregnancy: a still complicated diagnostic problem Tiziana Lazzarotto, Professor of Microbiology University of Bologna, Bologna, Italy
12:00 - 12:30
Clinical case 2: Postnatal treatment of CMV are we hearing the full story? Suzanne Luck, Hon Senior Lecturer, Consultant Paediatrician St George's University London, London, United Kingdom
12:30 - 13:00
Clinical case 3: CMV after transplantation-still a challenge Elisabeth Puchhammer Medical University of Vienna, Vienna, Austria
Speaker1 Speaker2 Speaker3
14:15 - 15:45
Meer info
Session B.04: Virus and Host

Chairs: Ed Mocarski  & Thomas Stamminger

14:15 - 14:45
Invited Lecture: Impact of placental immune responses on congenital HCMV transmission and pathogenesis Dana Wolf, Head, Clinical Virology Unit Hadassah University Hospital, Jerusalem, Israel
14:45 - 15:15
Lessons from an epidemic: Patterns of Cytomegalovirus and Zika virus infection modeled in the human placenta ex vivo Lenore Pereira Universityof California San Francisco, San Francisco, Ca, United States of America
15:15 - 15:30
A clinical CMV isolate passaged on fibroblasts in the presence of hyperimmuneglobulin retains epithelial tropism and an intact UL128-131A locus Michael McVoy Virginia Commonwealth University, RICHMOND VIRGINIA, United States of America
15:30 - 15:45
CRISPR/Cas9-mediated genome editing of human cytomegalovirus limits productive infection Emmanuel Wiertz University Medical Center Utrecht , Utrecht, Netherlands
Speaker1 Speaker2 Speaker3
16:00 - 17:00
Meer info
Poster Presentation Track B

Poster presenters will be standing by their poster to answer questions from Conference delegates. An overview of the posters per track can be found HERE.

Speaker1 Speaker2 Speaker3
Wednesday 3 May 2017
08:30 - 10:25
Meer info
Session C.03: Clinical Practice, Problems & Solutions

Chairs: Mark Wills & Wendy Van Zuijlen

08:30 - 09:00
Invited Lecture: An economic view on T cells: Inflation and deflation Annette Oxenius, Professor of Immunology ETH Zürich, Zürich, Switzerland
09:00 - 09:40
Keynote Lecture: Adoptive T cell therapy of CMV infection Dirk H. Busch, Director Technische Universität München, München, Germany
09:40 - 09:55
Analysis of T cells targeting human cytomegalovirus by Next Generation Sequencing Alina Huth Helmholtz Zentrum München, Munich, Germany
09:55 - 10:10
Interaction between soluble HLA-G expression and HCMV infection during pregnancy Tiziana Lazzarotto, Professor of Microbiology University of Bologna, Bologna, Italy
10:10 - 10:25
Neurodevelopmental outcome and hearing in early childhood of preterm infants with postnatal cytomegalovirus infection Joppe Nijman University Medical Center Utrecht, Utrecht, Netherlands
Speaker1 Speaker2 Speaker3
10:55 - 13:05
Meer info
Session B.05: Virus and Host

Chairs: Melanie Brinkmann & Ramon Arens

10:55 - 11:35
Keynote Lecture: CMV-driven immunosenescence : mechanisms and management Paul Moss, Director of Research in College of Medicine University of Birmingham, Birmingham, United Kingdom
11:35 - 12:05
Invited Lecture: Mononuclear phagocyte subset activation and functions during murine cytomegalovirus infection Marc Dalod, Team leader ‘Dendritic cells and antiviral defense' CNRS, Marseille, France
12:05 - 12:20
Human cytomegalovirus infection enhances the expression of genes critical for neural cell migration in neural stem cells and fetal brain Stéphane Chavanas Centre de Physiopathologie Toulouse Purpan, INSERM UMR 1043, Toulouse, France
12:20 - 12:35
A New Strain of Guinea Pig CMV Suggests a More Prudent Strategy for Evaluation of Interventions Against Congenital CMV K. Yeon Choi Texas A&M University Health Science Center, College Station, United States of America
12:35 - 12:50
Breast milk HCMV viral load drives the establishment of breast milk CMV-pp65-specific CD8 T cells in HCMV infected mothers. Steffanie Sabbaj University of Alabama at Birmingham, Birmingham, United States of America
12:50 - 13:05
The UL40 homologue Rh67 is required for the induction of MHC-E-restricted CD8+ T cells by RhCMV Klaus Früh, Senior Scientist, Professor, Molecular Microbiology & Immunology Oregon Health & Science University , Beaverton, United States of America
Speaker1 Speaker2 Speaker3
14:00 - 15:45
Meer info
Session A.02: Epidemiology & Burden of Disease

Chairs: Shannon Ross & Marianne Leruez-Ville

14:00 - 14:20
LATE BREAKER: A phase II Randomized Double-Blind Placebo-Controlled Trial of Ganciclovir to Prevent Cytomegalovirus Reactivation in Acute Critical Illness [‘GRAIL’ Study] Michael Boeckh, Head, Infectious Disease Sciences Program University of Washington, Seattle, United States of America
14:20 - 14:45
Invited Lecture: Congenital CMV infection: can we predict long-term outcome? Ann Vossen, Clinical Virologist Leiden University Medical Center , Leiden, Netherlands
14:45 - 15:00
Neuroimaging findings as potential predictors of adverse outcomes in asymptomatic congenital CMV infection (cCMV) identified at birth Aparecida Yulie Yamamoto Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
15:00 - 15:15
Outcomes From a State-wde Hearing-Targeted Cytomegalovirus Screening Program Albert Park University of Utah, Salt Lake City, United States of America
15:15 - 15:45
Infectious Reactivation of Cytomegalovirus Explaining Age- and Sex-Specific Patterns of Seroprevalence Michiel Van Boven National Institute for Public Health and the Environment, Bilthoven, Netherlands
15:30 - 15:45
Increasing Awareness and Promoting Strategies for Prevention of Congenital Cytomegalovirus Infection (cCMV) Among Young Pregnant Women Karen Fowler University of Alabama at Birmingham, Birmingham, United States of America
Speaker1 Speaker2 Speaker3
15:45 - 16:15
Meer info
Commercial session by QIAGEN

Improved management of CMV infections with Viral Load and IGRA testing in combination.
Christophe Salanon, Business Development Manager, QIAGEN

Speaker1 Speaker2 Speaker3
16:00 - 17:00
Meer info
Poster Presentation Track C & Track D

Poster presenters will be standing by their poster to answer questions from Conference delegates. An overview of the posters per track can be found HERE.

Speaker1 Speaker2 Speaker3
17:00 - 18:15
Meer info
Session B.06: Virus and Host

Chairs: Luka Cicin-Sain & Chris Benedict

17:00 - 17:30
Invited Lecture: Antibody and/or T-cell driven design for a protective HCMV vaccine? Daniele Lilleri, Researcher Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
17:30 - 17:45
The endothelin B receptor is critical for human cytomegalovirus infection in endothelial cells and a potential target for anti-viral therapy Masany Jung Karolinska Insititute, Stockholm, Sweden
17:45 - 18:00
Late-rising CD4 T cells resolve CMV persistence Chris Benedict, Associate Professor La Jolla Institute for Allergy and Immunology, La Jolla, United States of America
18:00 - 18:15
In Wildtype HCMV, the Pentameric Complex Drives Efficient Direct Cell-Cell Transmission that is Resistant to Host Immune Defenses Richard Stanton Cardiff University, Cardiff, United Kingdom
Speaker1 Speaker2 Speaker3
21:00 - 21:15
Meer info
Award session

Presentation of the CMV 2017 award for the two best Poster.

During the Conference the Poster Committee, Ed Mocarski,
Ramon Arens and Tiziana Lazzarotto will select the two best
posters from all the submitted abstracts.

 

 

 

Speaker1 Speaker2 Speaker3
Thursday 4 May 2017
08:30 - 10:25
Meer info
Session D.01: Treatment and Prevention

Chairs: Stuart Adler & Suresh Boppana

08:30 - 09:10
Keynote Lecture: CMV drug development: current landscape, challenges and opportunities Veronica Miller, Executive Director Forum for Collaborative Research, Washington DC, United States of America
09:10 - 09:25
Live-CMV vaccines lacking viral MHC I homologs are attenuated in guinea pigs but confer sterilizing immunity against congenital CMV transmission Mark Schleiss, Division Director, Pediatric Infectious Diseases Uiversity of Minnesota, Minneapolis, United States of America
09:25 - 09:40
Active evolution of memory B-cells specific for viral gH/gL/pUL128-131 pentameric complex in healthy subjects with silent human cytomegalovirus infection Tong-Ming Fu Merck Sharp and Dohme Company, West Point, United States of America
09:40 - 09:55
The breadth of synthetic long peptide vaccine-induced CD8+ T cell responses determines the efficacy against mouse cytomegalovirus infection Eleni Panagioti LUMC, Leiden, Netherlands
09:55 - 10:10
Novel antivirals for the prevention and treatment of congenital CMV Stuart Hamilton Virology Research Laboratory, SEALS Microbiology, Sydney, Australia
10:10 - 10:25
A CMV vaccine based on non-replicating lymphocytic choriomeningitis virus vectors expressing gB and pp65 is safe and immunogenic in man Anders Lilja Hookipa Biotech AG, Vienna, Austria
Speaker1 Speaker2 Speaker3
10:55 - 12:20
Meer info
Session D.02: Treatment and Prevention

Chairs: Debbie van Baarle & Mark Schleiss

10:55 - 11:10
CMV-specific CD4+ T cells in CMV-IgG-seronegative individuals protect from CMV viremia following transplantation with a CMV-seropositive donor kidney Nicolle Litjens, Senior Scientist Erasmus Medical Center, Rotterdam, Netherlands
11:10 - 11:25
KLRG1+ CD8 T cells induced by cytomegalovirus vector expressing NKG2D ligand RAE-1γ provide robust protection against tumor challenge Tihana Trsan Faculty of Medicine, University of Rijeka, Rijeka, Croatia
11:25 - 11:40
Disabled Infectious Single Cycle (DISC) Cytomegalovirus Vaccine Encoding Pentameric Complex is Completely Protective Against Congenital Guinea Pig CMV Alistair McGregor Texas A&M University Health Science Center, College Station, United States of America
11:40 - 12:20
Keynote Lecture: A CMV Vaccine Can Be Made Now Stanley Plotkin, Emeritus Professor University of Pennsylvania, Doylestown, United States of America
Speaker1 Speaker2 Speaker3
12:20 - 12:45
CMV 2017: the 6th International congenital CMV conference/16th International CMV/betaherpesvirus workshop in 2017<